2018年3月21日星期三

Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: Assessment of composite end-points

Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: Assessment of composite end-points

D Yabe, H Kuwata, R Usui, T Kurose, Y Seino - 2015 - Taylor & Francis
Abstract Assessment of the benefits of anti-diabetic drugs for type 2 diabetes requires
analysis of composite end-points, taking HbA1c, bodyweight, hypoglycemia and other
metabolic parameters into consideration; continuous, optimal glycemic control as well as …


For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to >99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.

Eva He
eva@pepmic.com
Pepmic Co., Ltd
www.pepmic.com


没有评论:

发表评论